KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.24, no.3, pp.235-247, 2014 (Peer-Reviewed Journal)
Article / Article
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
Science Citation Index Expanded, Scopus, TR DİZİN (ULAKBİM)
schizophrenia, schizoaffective disorder, psychotropic, polypharmacy, drug interaction, TORSADE-DE-POINTES, ANTIPSYCHOTIC POLYPHARMACY, QTC PROLONGATION, BIPOLAR DISORDER, PLASMA-LEVEL, LITHIUM, PRESCRIPTION, PREVALENCE, INPATIENTS, RISPERIDONE
Objective: The rate of polypharmacy is increasing in patients with psychotic disorders. Polypharmacy is defined as the concomitant use of two or more drugs at a time. As most psychotropic medications are metabolized via the cytochrome enzyme system, it is easy to predict that polypharmacy will increase the risk of drug-drug interactions. This study was planned to evaluate the interaction risks of medications used by patients with a diagnosis of schizophrenia and schizoaffective disorder.